Ardelyx adds $50 m liquidity, locks in SOFR-linked credit through 2030

Rhea-AI Filing Summary

Ardelyx, Inc. (ARDX) has amended its February 2022 Loan & Security Agreement for the fifth time, securing an immediate $50 million senior secured term loan ("Term E") and gaining access to an additional $100 million of committed capital in two optional $50 million tranches ("Term F" and "Term G").

Key economics include: (1) Term E pricing at 4.00% plus 0.022% plus 1-month SOFR, with a SOFR floor of 4.70%; (2) optional Term F/G pricing at SOFR + 4.95%, floored at 3.50%; (3) interest-only payments until maturity—July 1, 2028 for Term E and July 1, 2030 for Term F/G. The company paid a $250k draw fee for Term E and a $1.0 million facility fee for the incremental loans.

The facility remains collateralized and carries back-end fees of 4.95% (Term E) and 3.45% (Term F/G) of principal, payable upon maturity, acceleration, or prepayment. No changes were disclosed to covenants or security packages.

Investment view: The amendment immediately bolsters liquidity and provides flexible growth or runway capital through 2026, but materially increases secured debt capacity and locks in high floating-rate interest costs. Investors should weigh the near-term cash benefit against potential future leverage and interest-expense drag.

Positive

• $50 million immediate liquidity strengthens cash runway without equity dilution.
• $100 million committed option gives flexibility to fund operations or growth through 2026.
• Interest-only payments until 2028/2030 minimize near-term cash outflow.
• Extended maturities (2030 for incremental loans) defer principal risk.

Negative

• High floating-rate spreads (SOFR +4.0–4.95%) increase interest expense.
• Secured debt capacity rises, potentially elevating leverage and covenant pressure.
• Back-end fees of 3.45–4.95% add several million in future obligations.
• Exposure to SOFR rate volatility may further escalate cost of capital.

Insights

Sell-Side Biotechnology Analyst

TL;DR: New $50 m draw plus $100 m option strengthens liquidity through 2026; cost of capital remains elevated.

Ardelyx gains non-dilutive liquidity exactly when commercial ramp-up of tenapanor demands working capital. The $50 m draw extends cash runway and the $100 m committed option provides strategic flexibility for launch scaling or contingency planning without revisiting equity markets. Interest-only structure through 2028/2030 limits near-term P&L impact, but SOFR-linked pricing above 9% (at current SOFR) implies ~$4-5 m in annual interest for Term E alone. Net leverage could rise markedly if both incremental tranches are tapped, warranting attention to covenant headroom and future financing mix. Overall, liquidity positive outweighs cost negative.

Credit Risk Analyst

TL;DR: Amendment raises secured debt capacity and embeds sizable back-end fees, moderately heightening leverage risk.

The facility preserves the existing 2028 maturity for legacy loans while layering incremental 2030 maturities, effectively back-loading amortization risk. The 4.95% final fee on Term E and 3.45% on incremental tranches add nearly $5 m of non-cash obligations on full draw. With floating-rate spreads near 500 bps, serviceability hinges on continued revenue traction. Absence of disclosed covenant relief suggests standard financial covenants remain; investors should monitor net debt/EBITDA thresholds. Impact assessment: manageable near term, but leverage profile deteriorates if incremental loans are executed without proportional earnings growth.

0001437402false00014374022025-06-302025-06-300001437402dei:OtherAddressMember2025-06-302025-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2025

ARDELYX, INC.

(Exact name of registrant as specified in its charter)

Delaware			001-36485			26-1303944
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification Number)

400 FIFTH AVE., SUITE 210, WALTHAM, MASSACHUSETTS 02451

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (510) 745-1700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001

ARDX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 1.01    Entry into a Material Definitive Agreement.

On June 30, 2025, Ardelyx, Inc. (the “Company”) entered into a Fifth Amendment (the “Fifth Amendment”) to the Loan and Security Agreement, dated February 23, 2022, by and among the Company, as borrower, SLR Investment Corp. (“SLR”), as collateral agent and the lenders party thereto.

The Fifth Amendment, among other things, (1) provided for the immediate draw of the principal amount of $50.0 million (the “Term E Loan”) on the closing date of the Fifth Amendment and (2) provides the Company with the option to draw an additional $100.0 million of committed senior secured term loans, consisting of two separate term loans, each in a principal amount of $50.0 million: (a) the first of which is available at the Company’s election through June 30, 2026 (the “Term F Loan”) and (b) the second of which is available at the Company’s election through December 20, 2026 (the “Term G Loan” and, together with the Term F Loan, the “Incremental Term Loans”).

The interest rate for the Term E Loan is 4.00% plus a rate equal to 0.022% plus the 1-month SOFR reference rate, subject to a SOFR floor of 4.70%. The interest rate for the Incremental Term Loans, if drawn, will be 4.95% plus the 1-month SOFR reference rate subject to a SOFR floor of 3.50%.

On the effective date of the Fifth Amendment, the Company paid (i) a fee of $250 thousand in connection with the funding of the Term E Loan, and (ii) a facility fee of $1.0 million with respect to the Incremental Term Loans.

The maturity date for the Term E Loan (and the other existing term loans) remains July 1, 2028 (the “Maturity Date for the Existing Term Loans”). The Company is permitted to make interest-only payments on the Term E Loan through the Maturity Date for the Existing Term Loans. The maturity date for each of the Incremental Term Loans will be July 1, 2030 (the “Maturity Date for the Incremental Term Loans”). The Company will be permitted to make interest-only payments on the Incremental Term Loans from the date the Incremental Term Loan is drawn through the Maturity Date for the Incremental Term Loans.

The Company is obligated to pay a final fee equal to 4.95% of the Term E Loan upon the earliest to occur of (i) the Maturity Date for the Existing Loans, (ii) the acceleration of the Term E Loan, and (iii) the prepayment, refinancing, substitution, or replacement of the Term E Loan. A non-refundable final fee will be payable upon the earlier of any final termination, acceleration, prepayment, or the Maturity Date for the Incremental Term Loans, equal to 3.45% of the original principal amount of the Incremental Term Loans funded.

The above summaries of the material terms of the Fifth Amendment do not purport to be complete and are qualified in their entirety by reference to the Fifth Amendment, a copy of which is filed as Exhibit 10.1, respectively, to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
10.1						Fifth Amendment to Loan and Security Agreement, dated June 30, 2025, by and among the Company, SLR Investment Corp., as collateral agent, and the lenders party thereto.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 3, 2025			ARDELYX, INC.
			By:			/s/ Justin A. Renz
						Justin A. Renz
						Chief Financial and Operations Officer

FAQ

What did Ardelyx (ARDX) announce in its June 30, 2025 Form 8-K?

The company entered a Fifth Amendment to its 2022 loan agreement, drawing $50 m immediately and securing options for an additional $100 m.

How much new capital did Ardelyx receive immediately?

$50 million via the new Term E Loan funded on June 30, 2025.

What are the interest rates on the new loans?

Term E: 4.00% + 0.022% + 1-month SOFR (floor 4.70%). Incremental Term F/G: 4.95% + 1-month SOFR (floor 3.50%).

When do the new loans mature?

Term E matures on July 1, 2028; Term F and Term G mature on July 1, 2030.

What upfront and back-end fees are associated with the facility?

Ardelyx paid a $250k draw fee for Term E and a $1.0 m facility fee for the incremental loans; final fees equal 4.95% (Term E) and 3.45% (Term F/G) of principal.